Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico
Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico: Clinical Correlation and Effect of Its Supplementation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- Universidad de Guadalajara
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Intervention group: Patients with positive PCR for COVID-19 of both sexes supplemented with vitamin D
- Control group: Patients with positive PCR for COVID-19 of both sexes
- Both groups: Mexican individuals, after signing the informed consent letter and over 18 years of age.
Exclusion criteria:
• Diseases that compromise the absorption of Vitamin D; Crohn's disease, cystic fibrosis, and celiac disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention group
Formed by 22 patients that received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
|
Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
|
|
No Intervention: Control group
Formed by 20 patients that did not receive supplementation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline levels of serum vitamin D in COVID-19 patients
Time Frame: At baseline
|
Evaluate serum levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
|
At baseline
|
|
Correlation between D-dimer and vitamin D serum levels in COVID-19 patients
Time Frame: At baseline
|
Serum levels of D-dimer (ng/mL) will be measured at baseline and correlated with levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
|
At baseline
|
|
Correlation between transferrin and vitamin D serum levels in COVID-19 patients
Time Frame: At baseline
|
Serum levels of transferrin (mg/dL) will be measured at baseline and correlated with levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
|
At baseline
|
|
Correlation between ferritin and vitamin D serum levels in COVID-19 patients
Time Frame: At baseline
|
Serum levels of ferritin (ng/mL) will be measured at baseline and correlated with levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
|
At baseline
|
|
Effects of vitamin D3 supplementation on COVID-19 patients
Time Frame: After 14 days of supplementation
|
Serum levels of 25(OH)D (ng/mL) will be determined in the intervention group after 14 days of Vitamin D3 supplementation
|
After 14 days of supplementation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: José F Muñoz-Valle, Dr., University of Guadalajara
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
Other Study ID Numbers
- CI-07620
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
NCT04981769Not yet recruiting
-
NCT04885764Recruiting
-
NCT04608305Completed
-
NCT04864925Completed
-
NCT05045846Completed
-
NCT04973735Active, not recruiting
-
NCT04773756Completed
Clinical Trials on Vitamin D3
-
NCT07620236Not yet recruitingInfant Vitamin K Status | Vitamin K Deficiency Bleeding
-
NCT07448844RecruitingPlantar Wart | Wart | Common Wart | Warts Hand | Flat Wart | Viral Wart | Common Warts (Verruca Vulgaris) | Warts of Foot
-
NCT01430793Completed
-
NCT00412087CompletedVitamin D Deficiency | Pregnancy
-
NCT07196670Not yet recruitingPlantar Warts Treatment
-
NCT01751646Completed
-
NCT02395081CompletedVitamin D Deficiency | Pregnancy
-
NCT01695460CompletedMigraine According to International Headache Society (IHS) Criteria (ICHD-II)
-
NCT07177157Not yet recruitingCrohn Disease (CD) | Ulcerative Colitis (UC) | IBD (Inflammatory Bowel Disease)